ライフサイエンスコーパス: liver metastasis

1 ted by CNN may have the potential to predict liver metastasis.

2 se expression is a consistent feature of CRC liver metastasis.

3 a curative therapy for the treatment of CRC liver metastasis.

4 erapy in patients with resectable colorectal liver metastasis.

5 ociated with CRC in orthotopically generated liver metastasis.

6 by L1 overexpression in driving motility and liver metastasis.

7 eloid populations previously associated with liver metastasis.

8 F-kappaB pathway that has been implicated in liver metastasis.

9 metastasis of melanoma and MC38 colon cancer liver metastasis.

10 lantation procedures and demonstrated robust liver metastasis.

11 tastasis and also plays an important role in liver metastasis.

12 gross metastases in an intrasplenic model of liver metastasis.

13 proved respectability rates in patients with liver metastasis.

14 cant higher risk of advanced tumor stage and liver metastasis.

15 r neutrophils in the early adhesive steps of liver metastasis.

16 osurvival effect of TNF-alpha and to inhibit liver metastasis.

17 mportant role in mediating colorectal cancer liver metastasis.

18 hioate backbone in a mouse model of melanoma liver metastasis.

19 owing curative intent surgery for colorectal liver metastasis.

20 samples as well as association of AQP5 with liver metastasis.

21 so found to be increased in lung tissue with liver metastasis.

22 topathologic findings, including parenchymal liver metastasis.

23 igh Ki67 proliferation index and presence of liver metastasis.

24 associations with recurrence, survival, and liver metastasis.

25 l ablation (RFA) in patients with colorectal liver metastasis.

26 inical utility of CS-682 in the treatment of liver metastasis.

27 positive primary status, and size of largest liver metastasis.

28 ivity in vivo significantly promoted distant liver metastasis.

29 ly decreased the incidence of lymph node and liver metastasis.

30 G1 (dnG1) construct in a nude mouse model of liver metastasis.

31 provide added value in evaluating carcinoid liver metastasis.

32 9, 119 without liver metastasis and 122 with liver metastasis.

33 ls enrichment of this population may predict liver metastasis.

34 rapy represents a potential therapy for PDAC liver metastasis.

35 ples, including early-stage patients without liver metastasis.

36 ntial of targeting CD36 as immunotherapy for liver metastasis.

37 PY-5 receptor (Y5R) which is correlated with liver metastasis.

38 d CAF activation in mice and MC38 colorectal liver metastasis.

39 cleaved PARP) in tumour tissues and inhibits liver metastasis.

40 fied in a progressing small-cell-transformed liver metastasis.

41 ases) have been identified in the process of liver metastasis.

42 verexpression enhanced lung colonization and liver metastasis.

43 glucan (odetiglucan) treatment by inhibiting liver metastasis.

44 the colon and reduced primary tumor-derived liver metastasis.

45 d evidence for efficacy for the treatment of liver metastasis.

46 cs that could be predictive for metachronous liver metastasis.

47 select patients with unresectable colorectal liver metastasis.

48 and reveal potential targets to inhibit PDAC liver metastasis.

49 dies, with BIBO3304 significantly decreasing liver metastasis.

50 hment of a pro-metastatic niche and inhibits liver metastasis.

51 iver metastasis compared to subjects without liver metastasis.

52 us cycle of perimetastatic NPY secretion and liver metastasis.

53 cascades, which promotes CRC development and liver metastasis.

54 esenchymal-to-epithelial transition (MET) in liver metastasis.

55 role of endothelial Notch activation during liver metastasis.

56 was identified in samples from patients with liver metastasis.

57 eracting partner that promotes breast cancer liver metastasis.

58 t growth of cancer cells and is required for liver metastasis.

59 fibrosis is essential to the development of liver metastasis.

60 and understand their potential in targeting liver metastasis.

61 ncreased liver endothelial cell adhesion and liver metastasis.

62 herapy alone for patients with breast cancer liver metastasis.

63 upon CCSC detection, all subjects exhibited liver metastasis.

64 y-based drug and sunitinib markedly promotes liver metastasis.

65 mour cell challenge prevented development of liver metastasis.

66 id cells on cancer cells in a mouse model of liver metastasis.

67 a (RCC), colorectal carcinoma, or colorectal liver metastasis.

68 survival in mouse models of breast and lung liver metastasis.

69 large number of patients with CRC also have liver metastasis.

70 exosomal integrin alphavbeta5 was linked to liver metastasis.

71 ary tumors, 22 (36.1%) from LNMs, and 1 from liver metastasis (1.6%).

72 yroidal extension signified a strong risk of liver metastasis (19%, OR 23), whereas no clinical-patho

73 Of the 70 patients, 36 had colorectal liver metastasis, 24 had cholangiocarcinoma, 4 had hepat

74 ponse rate was higher among patients without liver metastasis (3 of 13 individuals [23.1%]) vs with l

75 stasis (3 of 13 individuals [23.1%]) vs with liver metastasis (4 of 69 individuals [5.8%]).

76 le prediction models for 5-year metachronous liver metastasis (5YLM) using combinations of clinical v

77 te PET/CT accurately predicts the success of liver metastasis ablation at 1 y and is superior to imme

78 how that mouse models of orthotopic pMMR CRC liver metastasis accurately recapitulate the inefficacy

79 colleagues identified Pip4k2c as a driver of liver metastasis, acting by sensitizing cancer cells to

80 f per-lesion sensitivity in the detection of liver metastasis, all three readers had higher diagnosti

81 Liver metastasis along with MMP-9 activation and the pro

82 differential responses, with lymph node and liver metastasis among the most and least responsive, re

83 wed from 1/1/2000 to 12/31/2019, 119 without liver metastasis and 122 with liver metastasis.

84 All 11 patients (100%) showed liver metastasis and 8 patients (62%) also showed extrah

85 Our results indicate that liver metastasis and associated inflammation in mice wer

86 For women with no definite liver metastasis and at least one hepatic lesion conside

87 lonization in preclinical models of lung and liver metastasis and correlated with improved clinical o

88 late TGF-beta signature accurately predicted liver metastasis and discriminated HCC cell lines by deg

89 sustaining development of colorectal cancer liver metastasis and identify a potential target for ant

90 hotopic models, NID2 CRISPRi tumors had less liver metastasis and increased survival, highlighting NI

91 d the effect of a high-fat diet in promoting liver metastasis and induction of colonic CSC expansion.

92 stasis to the lung has higher TS levels than liver metastasis and is less responsive to treatment wit

93 A plasmid was an effective treatment against liver metastasis and moderately effective against lung m

94 on or using laparoscopic ultrasound (surface liver metastasis and peritoneal deposits).

95 in primary CRC significantly correlated with liver metastasis and poor patient survival.

96 igh levels of MCM2/3/4/6 are associated with liver metastasis and poor survival in prostate cancer pa

97 at Fv-p53 treatment had a profound effect on liver metastasis and represent the first demonstration o

98 le for IL-17A-producing gammadeltaT cells in liver metastasis and therapeutic resistance, offering ne

99 ith lung metastasis, 58 patients (8.1%) with liver metastasis, and 34 patients (4.8%) with bone metas

100 und to be upregulated in human colon cancer, liver metastasis, and melanoma progression.

101 for biomarker analysis) rate, complications, liver metastasis, and overall survival.

102 malignant pleural effusion, intraparenchymal liver metastasis, and residual tumor size were significa

103 reatic ductal adenocarcinoma with or without liver metastasis, and showed a significant increase in s

104 ons, especially hepatocellular carcinoma and liver metastasis, and the surveillance after percutaneou

105 ar survival following surgery for colorectal liver metastasis approaches 50%, over one-half of patien

106 er resection for advanced breast cancer with liver metastasis are lacking.

107 recurrence following surgery for colorectal liver metastasis are limited.

108 e the major population of immunosuppressive, liver metastasis-associated macrophages (LMAM), while th

109 al radioembolization (TARE) of breast cancer liver metastasis (BCLM) on antitumor immunity is unknown

110 ent mismatch repair tumors and those without liver metastasis benefited more from dual inhibition of

111 adiofrequency ablation [RFA]) for colorectal liver metastasis between 1982 and 2008 were identified f

112 a critical role in colon cancer invasion and liver metastasis, but the mechanistic features of this p

113 m cells (CSC) and promotes colorectal cancer liver metastasis by binding to the Nanog promoter and en

114 w TNF signaling influences the efficiency of liver metastasis by colon and lung carcinoma in mice tha

115 Myeloid cells promote liver metastasis by down-regulating ANGPTL7 expression i

116 Claudin-2 promotes breast cancer liver metastasis by enabling seeding and early cancer ce

117 bition of in vitro proliferation and in vivo liver metastasis by p85alpha or p110alpha siRNA treatmen

118 were implanted with 5 x 10(6) rat colorectal liver metastasis cell line cells.

119 for local tumor control following colorectal liver metastasis (CLM) ablation.

120 ion could be an option for some colon cancer liver metastasis (CLM) patients, specifically, as a salv

121 -associated macrophages (TAMs) in colorectal liver metastasis (CLM) represents a correlate of functio

122 frequency (RF) ablation of colorectal cancer liver metastasis (CLM).

123 icantly associated with left-sided tumor and liver metastasis compared to BRAF V600E mutation (P = 0.

124 lung metastasis and MDR1/LDH-A expression in liver metastasis compared to human primary PDAC tumors.

125 with no evidence of PC, and in subjects with liver metastasis compared to subjects without liver meta

126 melanoma cells into mice resulted in reduced liver metastasis compared with CXCR4-positive uveal mela

127 aying the onset and inhibiting the growth of liver metastasis compared with gemcitabine, 5-FU, and co

128 ession of 14 genes in the primary cancer and liver metastasis compared with normal mucosa.

129 (CRC) is prevalent with high mortality, with liver metastasis contributing as a major factor that wor

130 ed on a set of three human colorectal cancer liver metastasis (CRCLM) tissue sections.

131 ublished on hepatic resection for colorectal liver metastasis (CRLM) and determine whether a negative

132 Among patients with colorectal liver metastasis (CRLM) who are eligible for curative-in

133 For colorectal liver metastasis (CRLM), intrahepatic lymph invasion and

134 residing and resulting in Colorectal cancer liver metastasis (CRLM).

135 levated in urine of patients with colorectal liver metastasis (CRLM).

136 ritical for the formation and maintenance of liver metastasis derived from colorectal cancers.

137 , yet anti-lymphangiogenesis does not impact liver metastasis despite abrogating lymph node metastasi

138 T1HI males showed increased risk for liver metastasis development not only in PC but also in

139 sults suggest that even though there were no liver metastasis during the primary colectomy, the featu

140 verexpression potentiated local invasion and liver metastasis effects, which were suppressed by reexp

141 In a surgical model of pancreatic cancer liver metastasis, eNOS overexpression in the tumor micro

142 pecially when the time to the development of liver metastasis exceeds 2 years.

143 Treatment of liver metastasis experiences slow progress owing to the

144 se is inefficient in colorectal cancer (CRC) liver metastasis following existing therapies due to abu

145 sendothelial migration, resulting in reduced liver metastasis formation in vivo Talin1 expression lev

146 er, our findings uncover a new mechanism for liver metastasis formation involving an active contribut

147 cting tumor-stroma interactions and favoring liver metastasis formation.

148 An indolent liver metastasis from a class 1B UM is infiltrated with

149 Despite these therapies, liver metastasis from breast cancer is associated with a

150 ng research of the mechanisms and tropism of liver metastasis from breast cancer will hopefully resul

151 d contrast-enhanced MDCT in the detection of liver metastasis from colorectal cancer (mCRC).

152 Liver metastasis from colorectal cancer is a leading cau

153 ic hernia after radiofrequency ablation of a liver metastasis from colorectal cancer.

154 rsies regarding LT as a treatment option for liver metastasis from CRC due to poor outcomes in previo

155 spheres have been used successfully to treat liver metastasis from DSRCT.

156 It is well known that patients with liver metastasis from metastatic castration-resistant pr

157 esponse rates for patients with unresectable liver metastasis from solid tumors.

158 from the primary tumor to the development of liver metastasis greater than 2 years was a significant

159 elumetinib (SEL) had significantly inhibited liver metastasis growth (p = 0.013 and p = 0.035, respec

160 ealed that CD44 knockdown increased lung and liver metastasis >10-fold, while metastasis was decrease

161 Patients with liver metastasis had worsen prognosis, conferring a 2.26

162 rs, current or former smokers, had no CNS or liver metastasis, had not EGFR mutation, and had high PD

163 following surgical management of colorectal liver metastasis have largely focused on overall surviva

164 st treatment imaging biomarker in colorectal liver metastasis however measurements are affected by re

165 r 2; HR, 1.46), loss of appetite (HR, 1.62), liver metastasis (HR, 1.32), >/= four metastatic sites (

166 acted from normal colon, primary cancer, and liver metastasis in a patient with metastatic colon canc

167 ignaling in MSI colon cancer cells increased liver metastasis in an orthotopic model in vivo.

168 ly impaired the growth of primary tumors and liver metastasis in an orthotopic mouse model of PDAC (m

169 ic cancer cells suppressed tumorigenesis and liver metastasis in an orthotopic nude mouse model, sugg

170 stimulated tumor cell invasion, and induced liver metastasis in an orthotopic xenograft mouse model

171 cancer cells in both local colonization and liver metastasis in animal study.

172 To investigate their role, we simulated liver metastasis in C57BL/6 mice through intrasplenic in

173 ng pathway as a key mediator of invasion and liver metastasis in colon cancer.

174 T cell depletion resulted in severe lung and liver metastasis in DMBA-treated PyMT mice.

175 at integrin alpha2 expression contributes to liver metastasis in human colorectal cancer.

176 es positively correlate with tumor grade and liver metastasis in human pancreatic neuroendocrine tumo

177 sly (SC), or in the spleen capsule to induce liver metastasis in immune-deficient mice.

178 asia to pancreatic ductal adenocarcinoma and liver metastasis in KPC mice.

179 hway with statins reduced cell migration and liver metastasis in mice consuming SSBs.

180 y efficient in preventing the development of liver metastasis in mice.

181 AMs) and deletion of CD36 in MAMs attenuates liver metastasis in mice.

182 2, reduced polyp numbers in Apc(Min/+) mice, liver metastasis in NSG mice with orthotopic tumors, and

183 Prevention of liver metastasis in vivo was tested by splenic injection

184 vitro, and impedes the tumour growth and the liver metastasis in vivo.

185 NFR2 antisense oligodeoxynucleotides reduced liver metastasis in wild-type mice.

186 cing lung metastasis but not affecting B16F1 liver metastasis, in fact, liver metastasis was enhanced

187 astatic uveal melanoma present with isolated liver metastasis, in whom the median survival is 6-12 mo

188 mours and matched PDX, from primary PDAC and liver metastasis, including a unique cohort of 5 'trios'

189 Liver metastasis increased in obese mice only at 4 weeks

190 Experiments quantifying lung and liver metastasis indicate that decreased survival of IFN

191 ls from a monogenomic primary tumour and its liver metastasis indicated that a single clonal expansio

192 An in vivo model of liver metastasis induced by human gastric carcinoma was

193 ntribute to the development of therapies for liver metastasis involving hepatic innate cells.

194 Liver metastasis is a major cause of mortality for patie

195 Liver metastasis is a major obstacle in treating aggress

196 Liver metastasis is a recalcitrant disease that usually

197 anical trapping of circulating tumour cells, liver metastasis is also dependent, at least in part, on

198 al for a patient with a solitary, resectable liver metastasis is better than that for a patient with

199 Liver metastasis is highly aggressive and treatment-refr

200 idence for a role of specific mucin genes in liver metastasis is lacking.

201 Since liver metastasis is the main cause of death in cancer pa

202 Liver metastasis is the major cause of CRC patient morta

203 Liver metastasis is the predominant cause of colorectal

204 ificantly correlated with the development of liver metastasis, its function in pancreatic cancer meta

205 he primary tumor (KMS 72; P = 0.0001) to the liver metastasis (KMS 25; tumor compared with metastasis

206 i-PD-L1 antibody significantly inhibited CRC liver metastasis, leading to long-term survival in mice.

207 000 proteins, we found unexpectedly that all liver metastasis lesions displayed a reproducible, zonal

208 section) or late (>6 months after resection) liver metastasis (LiM); extrahepatic metastasis (EHM); a

209 We extended these findings in our murine liver metastasis (LM) model, by treating tumor-bearing m

210 rts a dominant effect on MDSC programming in liver metastasis (LM).

211 merase I in lung metastasis as compared with liver metastasis, lung tumors had a 5-fold increase in E

212 We determined that concurrent liver metastasis, lymph node metastasis, Eastern Coopera

213 The sensitivity in detecting liver metastasis, lymph nodes, bone metastasis, and prim

214 ed patient, LDLT for unresectable colorectal liver metastasis may be justified, and patients should b

215 Similarly, in mouse models of CRC liver metastasis, mice fed with both glucose and fructos

216 In the liver metastasis model, 5 x 10(6) LS174T cells were inje

217 To establish a CRC liver metastasis model, we implanted mouse colon tumor M

218 m survival in an aggressive experimental CRC liver metastasis model.

219 ir ability to metastasize in an experimental liver metastasis model.

220 carcinoma BT549 cells using the experimental liver metastasis model.

221 in combination with IL-12 in a day 3 murine liver metastasis model.

222 antly decreases metastatic rates in the PDAC liver metastasis model.

223 ated Cu in a Wilson's disease model and in a liver metastasis model.

224 ent prostate cancer GEMMs and in a xenograft liver metastasis model.

225 mor model and greater than 1.5 %ID/g for the liver metastasis model.

226 In colorectal, pancreatic, and breast cancer liver metastasis models, we confirm the RLN gene therapy

227 Similar findings were observed in liver metastasis models.

228 ostic study, biologically derived colorectal liver metastasis molecular subtypes and integrated clini

229 promoter (RANTES-NIS-MSC) in a colon cancer liver metastasis mouse model established by intrasplenic

230 In liver metastasis mouse model, HTS01037 attenuated develo

231 nt SL, 95 had disseminated disease [(surface liver metastasis (n = 29) and peritoneal deposits (n = 6

232 rian (n = 12), lung (n = 19), and colorectal liver metastasis (n = 30) cancer patients who underwent

233 e liver metastasis (n = 5), deep parenchymal liver metastasis (n = 4), peritoneal deposits (n = 1), n

234 l 75 had unresectable disease due to surface liver metastasis (n = 5), deep parenchymal liver metasta

235 cer: n = 1 or metastatic disease [colorectal liver metastasis]: n = 14, ovarian cancer: n = 1, gastri

236 In patients with neuroendocrine liver metastasis (NELM), liver transplantation (LT) is a

237 sion profiles in primary mouse colon tumour, liver metastasis of colon cancer and naive colon tissues

238 DOX) nude mouse model of a highly aggressive liver metastasis of colon cancer.

239 mphangiogenic gene expression in primary and liver metastasis of colorectal cancer (CRC) and identify

240 ated with poor prognosis in both primary and liver metastasis of CRC.

241 x 10(9) PU; once a week, twice) directly to liver metastasis of five individuals with colon cancer a

242 Liver metastasis of Lewis lung carcinoma cells followed

243 ts showed that TrkBT1 overexpression induces liver metastasis of pancreatic cancer and uncovered a un

244 CD24 increases retroperitoneal invasion and liver metastasis of pancreatic cancer cells in an orthot

245 T also prevents retroperitoneal invasion and liver metastasis of pancreatic cancer cells.

246 body targeting ROBO1 significantly attenuate liver metastasis of PDAC by preventing the coadaptation

247 plantation) or into the spleen (experimental liver metastasis) of nude mice.

248 e then categorized by presence or absence of liver metastasis on pretreatment prostate-specific membr

249 of 273 patients, including 43 (15.75%) with liver metastasis on pretreatment PSMA PET/CT.

250 interactive effects of CYP2B6 genotypes and liver metastasis on the prognosis of metastatic breast c

251 MP-1 levels were correlated with synchronous liver metastasis or distant metastasis-associated diseas

252 usion: Our data suggest that the presence of liver metastasis predicts poorer outcomes in patients re

253 Randomization was stratified by liver metastasis (present versus absent).

254 h a previous diagnosis of breast cancer with liver metastasis presented with a complaint of increasin

255 ogy system and stratified by the presence of liver metastasis, previous docetaxel therapy, and diseas

256 ver resection in patients with breast cancer liver metastasis proved to be cost-effective when compar

257 bone marrow (BM) in patients with colorectal liver metastasis referred to surgery.

258 onmetastatic CRC cells prevented lung and/or liver metastasis, relative to control cells that did met

259 rocess, but their prometastatic functions in liver metastasis remain incompletely understood.

260 Ischemia reperfusion injury (IRI) during liver-metastasis resection for treatment of colon cancer

261 ecreased exosome uptake, as well as lung and liver metastasis, respectively.

262 RFP cancer cells were coinjected in the PV, liver metastasis resulted that contained GFP spleen cell

263 ired tumor growth and maintenance as well as liver metastasis, resulting in improved survival.

264 polymerase chain reaction on a cohort of 64 liver metastasis samples from patients with complete fol

265 trial in patients with resectable colorectal liver metastasis showed a significant reduction in progr

266 The liver metastasis showed drug-resistant CSC- and EMT-like

267 in colon cancer 1 (MACC1) levels measured in liver metastasis specimens to predict further recurrence

268 vanced stages of colorectal cancer (CRC) and liver metastasis, suggesting that it may play a role in

269 A murine liver metastasis syngeneic model of PDAC was treated wit

270 more likely to be absent in the progressing liver metastasis than those occurring pre-WGD, suggestin

271 iagnosis, Hispanics were less likely to have liver metastasis than whites (30% v 44%, respectively; P

272 transplantation for unresectable colorectal liver metastasis; these studies include the SECA Study (

273 ate of patients with unresectable colorectal-liver metastasis to complete resection with hepatic-arte

274 , which makes it unfavorable for established liver metastasis to grow.

275 C into these mice, was sufficient to restore liver metastasis to levels in wild-type mice.

276 een two groups of patients (with and without liver metastasis) to identify the metastasis-initiating

277 brosis repair mechanism can be leveraged for liver metastasis treatment via enforced RLN expression.

278 Survival for patients with colorectal liver metastasis undergoing left hepatic trisectionectom

279 vival data following treatment of colorectal liver metastasis using RFA with or without hepatic resec

280 th a splenic injection model of experimental liver metastasis using syngeneic MC38 colon cancer cells

281 Liver-metastasis variants having low to high metastatic

282 eraction that enables efficient formation of liver metastasis via intrasplenic injection.

283 onses were observed in 3 patients (21%) with liver metastasis vs 17 patients (63%) with nonliver meta

284 PSA response and OS for the 2 groups (liver metastasis vs. no liver metastasis) were compared

285 Median progression-free survival from liver metastasis was 5.2 months (95% CI: 3.7, 9.8; range

286 Median progression-free survival from liver metastasis was 8.1 months (95% CI: 6.4, 11.8; rang

287 The effect of pioglitazone on liver metastasis was assessed.

288 t affecting B16F1 liver metastasis, in fact, liver metastasis was enhanced in the absence of platelet

289 On multivariate analysis, the presence of liver metastasis was independently associated with short

290 The patient's liver metastasis was initially established subcutaneousl

291 ly, an enhanced spontaneous and experimental liver metastasis was observed in Cxcr2(-/-) mice compare

292 subjects with peritoneal carcinomatosis and liver metastasis were noted.

293 OS for the 2 groups (liver metastasis vs. no liver metastasis) were compared using chi(2) testing and

294 and mechanisms involved in colorectal cancer liver metastasis, which could be potential targets for d

295 leads to their escape from treatment and to liver metastasis, which in turn makes pancreatic ductal

296 also significantly inhibited lymph node and liver metastasis, which led to a significant increase in

297 rapy, systemic imaging identified a solitary liver metastasis, which was laparoscopically resected.

298 mouse model of pancreatic cancer diminished liver metastasis without altering primary tumor size.

299 rvival (OS) in the subgroup of patients with liver metastasis without disclosing the absolute duratio

300 Anti-angiogenesis inhibits liver metastasis, yet anti-lymphangiogenesis does not im